AENZ yields 103.09% · JNJ yields 2.13%● Live data
📍 AENZ pulled ahead of the other in Year 1
Combined, AENZ + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AENZ + JNJ for your $10,000?
Aenza S.A.A., together with its subsidiaries, engages in the Infrastructure, Energy, Engineering and Construction, and Real Estate management businesses in Peru, Bolivia, Chile, Mexico, and Colombia. The company's Infrastructure segment offers long-term concessions or similar contractual arrangements in Peru for three toll roads, the Lima Metro, a wastewater treatment plant in Lima, four producing oil fields, five multiple fuel storage facilities, and a gas processing plant, as well as operation and maintenance services for infrastructure assets. Its Engineering and Construction segment provides traditional engineering services, such as structural, civil, and design engineering; and services ranging from architectural planning to advanced specialties comprising process design, simulation, and environmental services. This segment also provides services related to civil works, which include construction of hydroelectric power stations and other large infrastructure facilities; electro mechanic construction, such as concentrator plants, oil, and natural gas pipelines, and transmission lines; and building construction comprising office and residential buildings, hotels, affordable housing projects, shopping centers, and industrial facilities, as well as procurement services; maintains plants and industrial facilities; and rents construction equipment. It serves mining, power, oil and gas, transportation, real estate, and other infrastructure sectors. The company's Real Estate segment develops and sells homes, and office and commercial spaces. The company was formerly known as Graña y Montero S.A.A. and changed its name to Aenza S.A.A. in November 2020. Aenza S.A.A. was founded in 1933 and is based in Surquillo, Peru.
Full AENZ Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.